Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

FDC Temettü

Temettü kriter kontrolleri 0/6

FDC şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

Ödeme oranı

Sektör ortalama getirisi	0.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₹0.800
Hisse başına kazanç	₹19.31
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 531599 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 531599 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

FDC Piyasaya Karşı Temettü Getirisi

531599 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (531599)	0%
Pazarın Alt %25'i (IN)	0.2%
Pazarın En İyi %25'i (IN)	1.0%
Sektör Ortalaması (Pharmaceuticals)	0.6%
Analist tahmini (531599) (3 yıla kadar)	0%

Önemli Temettü: 531599 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 531599 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 531599 Indian piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 531599 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

FDC Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent Director

FDC Limited, Annual General Meeting, Sep 26, 2024

First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)

FDC Limited to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)

FDC Limited Announces Board Completion of Tenure of Independent Directors

Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)

FDC Limited to Report Fiscal Year 2024 Results on May 29, 2024

FDC Limited, Annual General Meeting, Sep 27, 2023

FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)

FDC Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)

Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)

FDC Limited to Report Q3, 2023 Results on Feb 09, 2023

Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)

Price target increased to ₹375

FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent Director

FDC Limited to Report Q4, 2023 Results on May 23, 2023

First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)

FDC Limited to Report Q1, 2023 Results on Aug 04, 2022

Board Member recently bought ₹912k worth of stock

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

FDC Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹415

Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.

Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)

Price target decreased to ₹415

First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)

FDC Limited Launches Favipiravir Oral Suspension -Favenza

Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)

Price target raised to ₹470

New 90-day low: ₹280

Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)

FDC Limited to Report Q3, 2021 Results on Feb 04, 2021

New 90-day low: ₹311

Second quarter 2021 earnings released: EPS ₹5.15

Revenue and earnings beat expectations

New 90-day high: ₹368

New 90-day high - ₹349

FDC Limited to Report Q1, 2021 Results on Aug 07, 2020

FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.

First quarter earnings released

FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin